TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Telomir Pharmaceuticals, Inc. ( (TELO) ).
Telomir Pharmaceuticals, Inc. has announced new preclinical data indicating that its investigational compound, Telomir-1, significantly reduces intracellular iron levels in human keratinocytes more effectively than the FDA-approved iron chelator Deferoxamine (DFO). This discovery highlights Telomir-1’s potential in modulating iron levels, which is crucial for addressing oxidative stress and epigenetic regulation, factors linked to aging and various diseases. The findings suggest that Telomir-1 could play a significant role in advancing research on metal-ion homeostasis and its implications for cellular health.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of compounds that modulate metal-ion balance and oxidative stress. The company is engaged in pre-clinical research, particularly in the areas of aging and degenerative diseases, with a market focus on innovative treatments that address cellular health and epigenetic control.
Average Trading Volume: 3,000,482
Technical Sentiment Signal: Sell
Current Market Cap: $47.1M
For detailed information about TELO stock, go to TipRanks’ Stock Analysis page.